Prevalence of cytopenia(s) and somatic variants in patients with <i>DDX41</i> mutant germline predisposition syndrome
Yael Kusne(WinnMed), Mrinal M. Patnaik(Mayo Clinic), Cecilia Y. Arana Yi(Mayo Clinic in Arizona), Aref Al‐Kali(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic), Ludovica Marando(Wellcome/MRC Cambridge Stem Cell Institute), James M. Foran(Memorial Sloan Kettering Cancer Center), Timothy M. Chlon(Cincinnati Children's Hospital Medical Center), Jeanne Palmer(Mayo Clinic), Hassan B. Alkhateeb(Mayo Clinic), Alejandro Ferrer(Mayo Clinic), Christy M. Finke(Mayo Clinic), Talha Badar(Mayo Clinic in Florida), Mark R. Litzow(Mayo Clinic in Arizona), Naseema Gangat(Mayo Clinic in Arizona), David S. Viswanatha(Mayo Clinic), Terra L. Lasho(Mayo Clinic)
Cited by 10
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k